graft-versus-host disease

[Bone Marrow Transplantation] Investigators suggested that almost 80% of acute myeloid leukemia patients could undergo salvage therapy following relapse after front-line high-dose chemotherapy/autologous hematopoietic cell transplantation.

[Cell Reports Medicine] By combining hematopoietic stem cell (HSC) gene engineering and in vitro differentiation, scientists generated human allogeneic HSC-engineered invariant natural killer T cells at high yield and purity.

[Humanigen, Inc.] Humanigen, Inc. announced it plans to support a Phase II/III study to evaluate lenzilumab for the early treatment of acute graft versus host disease following allogeneic hematopoietic stem cell transplantation in collaboration with IMPACT.

[Scientific Reports] The genomic regions ranging from 500 base pairs upstream to 500 base pairs downstream of the eight SNPs that were reported as transplantation determinants by Petersdorf et al. were analyzed to evaluate whether genetic variants were associated with the survival status of patient

[Scientific Reports] Scientists revealed that three SNPs located in the intron or 3’-UTR of HLA-DOB regions are associated with the survival of patients in the recipient and donor-recipient matching groups, as well as cytomegalovirus infection/reactivation in the donor-recipient matching group.

[Bone Marrow Transplantation] The authors evaluated long-term outcome in 40 patients with myelodysplastic syndrome or acute myeloid leukemia, transplanted from related or unrelated donors following conditioning with targeted busulfan, fludarabine, and thymoglobulin.